TITAN BIOTECH LTD.

Titan Biotech Limited has announced its 34th Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 03:00 P.M. IST. The meeting will be conducted through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) in compliance with current regulations. Shareholders whose email addresses are not registered will receive a letter with a web-link to access the Annual Report and AGM Notice. The Annual Report for FY 2025-26 and the AGM Notice are available on the company's website.

Titan Biotech Ltd has filed its 34th Annual Report for the financial year 2025-26. The report, along with the notice for the 34th Annual General Meeting (AGM), is being disseminated electronically to shareholders. The AGM is scheduled for Tuesday, September 29, 2026, at 3:00 p.m. IST, to be conducted via Video Conferencing (VC) / Other Audio Visual Means (OA VM). The Annual Report details the company's financial and non-financial performance, strategic priorities, and value creation model, adhering to the Integrated Reporting Framework and Indian Accounting Standards. It is available on the company's website.

Titan Biotech Ltd has issued a notice for its 34th Annual General Meeting (AGM) scheduled for Tuesday, September 29, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM), in compliance with SEBI and MCA circulars. The company has also made its Annual Report for the financial year 2025-26 available to shareholders electronically and on its website. The Annual Report provides a comprehensive overview of the company's performance, strategy, governance, and value creation model for the fiscal year.

Titan Biotech Ltd has announced September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹0.50 per equity share for the financial year 2025-26. This dividend was recommended by the Board of Directors on May 30, 2026, and is subject to shareholder approval at the upcoming 34th Annual General Meeting (AGM). If approved, the dividend payment, after tax deduction, will be processed post-AGM. The company has fixed the record date in compliance with SEBI Listing Regulations.

Titan Biotech Ltd has announced that its 34th Annual General Meeting (AGM) will be held on September 29, 2026, at 3:00 PM IST via Video Conferencing/Other Audio Visual Means. The company has fixed September 22, 2026, as the Record Date for determining shareholder entitlement to the final dividend for the financial year ended March 31, 2026. The Register of Members and Share Transfer Books will be closed from September 23, 2026, to September 29, 2026, inclusive. E-voting will be open from September 26 to September 28, 2026.

Titan Biotech Ltd has announced the details for its 34th Annual General Meeting (AGM), scheduled for Tuesday, September 29, 2026, at 3:00 p.m. IST, to be conducted via Video Conferencing. The company has fixed Tuesday, September 22, 2026, as the Record Date for determining shareholder eligibility for the final dividend for the financial year ended March 31, 2026. Consequently, the Register of Members and Share Transfer Books will be closed from Wednesday, September 23, 2026, to Tuesday, September 29, 2026, inclusive. E-voting will be open from September 26 to September 28, 2026.

Titan Biotech's Board of Directors has approved a bonus issue of equity shares in a 1:4 ratio, subject to shareholder and regulatory approvals. The company also approved an increase in its authorized share capital to accommodate the bonus issue. Additionally, the Board recommended the re-appointment of Mr. Rohit Jain as an Independent Director for a second term and scheduled the 34th Annual General Meeting for September 29, 2026. The record date for the AGM and dividend payment is September 22, 2026, with book closure from September 23-29, 2026. A final dividend of Rs. 0.50 per share was also recommended.

Titan Biotech Ltd's Board of Directors has approved the issuance of bonus shares in a 1:4 ratio, subject to shareholder approval. The company also proposed an increase in authorized share capital from ₹10 crore to ₹10.40 crore to facilitate this bonus issue. Additionally, the Board recommended the re-appointment of Mr. Rohit Jain as an Independent Director for a second five-year term. The 34th Annual General Meeting is scheduled for September 29, 2026, with September 22, 2026, set as the cut-off date for voting eligibility and record date for a final dividend of ₹0.50 per share. Book closure is from September 23 to September 29, 2026.

Titan Biotech Ltd has announced that its Board of Directors will convene on September 3, 2026, to consider and approve a proposal for a bonus issue. The meeting will also finalize the details for the 34th Annual General Meeting (AGM), including the notice, director's report, book closure dates, and e-voting arrangements for the fiscal year ended March 31, 2026. Concurrently, the trading window for designated persons will be closed from August 31, 2026, until 48 hours after the board meeting's outcome is declared, in compliance with SEBI regulations.

Titan Biotech Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and connected persons. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The trading window will remain shut until 48 hours after the conclusion of the Board Meeting scheduled for Thursday, September 03, 2026. The primary purpose of this meeting is to consider a proposal for the issue of Bonus Shares, subject to necessary approvals. All relevant parties have been duly informed not to engage in any trading of the company's securities during this period.